Updated survival results of ALTER-C002: Anlotinib combined with CAPEOX as first-line treatment in RAS/BRAF wild-type unresectable metastatic colorectal cancer.

被引：0
|
作者：
Liu, Yue
Ding, Kefeng
Xiao, Qian
He, Jinjie
Hu, Hanguang
Du, Jinlin
Zhu, Yuping
Chen, Jiaqi
Liu, Zhuo
Wang, Jianping
Sun, Lifeng
Xu, Dong
Li, Jun
Liao, Xiujun
Wang, Jianwei
Cai, Yibo
Cai, Cheng
Jin, Zhekang
Yuan, Ying
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Dept Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Colorectal Surg, Jinhua Hosp, Jinhua, Zhejiang, Peoples R China
[5] Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Colorectal Surg, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 2, Dept Med Oncol, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 2, Colorectal Surg & Oncol,Sch Med, Key Lab Canc Prevent & Intervent,Minist Educ, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-3532-2370-7650-2700; 283-237-255; 281-206-4957-3975-3408-6824; 261-492-12161; 261-492-2769; 613-135-244-3829; 281-318-430; 5; 4; 2; 2414; 1589; 92; 239; 6; 3; 1; 38116-38094-8; 38092-34311; 38092-29234; 38092-18849;
D O I：
10.1200/JCO.2024.42.3_suppl.131
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：131 / 131
页数：1
相关论文
共 50 条
  • [41] Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer
    Kasper, S.
    Cheng, A-L.
    Overkamp, F.
    Rouyer, M.
    Foch, C.
    Lamy, F-X.
    Esser, R.
    Messinger, D.
    Rothe, V.
    Chen, W.
    Brodowicz, T.
    Zielinski, C. C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [42] Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
    Kasper-Virchow, Stefan
    Cheng, Ann-Lll
    Overkamp, Friedrich
    Rouyer, Magali
    Foch, Caroline
    Lamy, Francois-Xavier
    Esser, Regina
    Messinger, Diethelm
    Rothe, Vivien
    Chen, Wenfeng
    Brodowicz, Thomas
    Zielinski, Christoph
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 220
  • [43] Cost-effectiveness analysis of cetuximab combined with chemotherapy as a first-line treatment for patients with RAS wild-type metastatic colorectal cancer based on the TAILOR trial
    Wang, Huijuan
    Huang, Lingfei
    Gao, Peng
    Zhu, Zhengyi
    Ye, Weifeng
    Ding, Haiying
    Fang, Luo
    BMJ OPEN, 2020, 10 (02):
  • [44] First-line panitumumab versus bevacizumab in combination with mFOLFOX6 for RAS wild-type metastatic colorectal cancer: PARADIGM trial results
    Muro, K.
    Watanabe, J.
    Shitara, K.
    Yamazaki, K.
    Ohori, H.
    Shiozawa, M.
    Yasui, H.
    Oki, E.
    Sato, T.
    Naitoh, T.
    Komatsu, Y.
    Kato, T.
    Hihara, M.
    Soeda, J.
    Yamamoto, K.
    Akagi, K.
    Ochiai, A.
    Uetake, H.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S377 - S377
  • [45] Therapeutic effect of biweekly cetuximab combined with first-line chemotherapy on KRAS/RAS wild-type advanced colorectal cancer
    Li, Jing
    Li, Jianjiong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (10): : 12348 - 12355
  • [46] A phase 2 trial of sintilimab (IBI 308) in combination with CAPEOX and bevacizumab (BBCAPX) as first-line treatment in patients with RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer.
    Fang, Xuefeng
    Zhong, Chenhan
    Zhu, Ning
    Weng, Shanshan
    Hu, Hanguang
    Wang, Jian
    Xiao, Qian
    Wang, Jianwei
    Song, Yongmao
    Sun, Lifeng
    Xu, Dong
    Liao, Xiujun
    Dong, Caixia
    Zhang, Suzhan
    Li, Jun
    Ding, Ke-Feng
    Yuan, Ying
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Clinical practice use of panitumumab combined with chemotherapy in patients with wild-type RAS metastatic colorectal cancer.
    Hebart, Holger Frithjof
    Tomasek, Jiri
    Csoszi, Tibor
    Koukakis, Reija
    Kafatos, George
    Kuhn, Anja
    Bjorklof, Katja
    Buchler, Tomas
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [48] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [49] Cost-Effectiveness Analysis of Panitumumab Compared with Bevacizumab for First-Line Treatment of Patients with Wild-Type RAS Metastatic Colorectal Cancer in Germany
    Frank, M.
    Lange, A.
    Michailov, G.
    Lebioda, A.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2016, 21 (04): : 203 - 209
  • [50] Adverse event management costs for first-line treatment with cetuximab or panitumumab of RAS wild-type metastatic colorectal cancer patients in Latin America
    Pescott, Chris
    Kasle, Adam
    Esteso, Federico
    Stefani, Stephen
    Brust, Leandro
    Pinto, Jose
    Tilli, Malena
    Massello, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345